Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 5

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1
Chunk 5
---
 from human medical
device companies specifically for use in pets. In addition to commercializing our own products in strategic market sectors and in view
of the Company’s vast proprietary product pipeline, the Company may establish strategic out-licensing partnerships to provide secondary
revenues.

5

In
February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their Precise PRP (Platelet-Rich
Plasma) product for both canine and equine. Revenues are expected in fiscal year 2026.

Product
Pipeline: Other Potential Biocoacervate and Protein Based Products

Below
is a listing of applications of our technology that we plan to commercialize or out-license to strategic partners:

Dermal
Filler

Our
biomaterials are constructed from purified water, protein, and carbohydrate, tailored to simulate different body tissues that biologically
integrate (bio-integration). Our biomaterials can be manufactured and used as a dermal filler for wrinkle treatment by injection. These
formed, gel particles fill, integrate and rejuvenate dermal skin tissue to remove the wrinkle. This product was taken through an FDA
clinical trial under the name CosmetaLife®, see the results here: www.clinicaltrials.gov (NCT00414544).

Cardiovascular
Devices

Our
blood-compatible biomaterial, which allows blood contact and bio-integrative processes to occur without clotting, platelet attachment,
or thrombogenesis, is used to repair cardiovascular tissue. VasoGraft®, a blood vessel graft made from VasoCover™
material, is designed to mimic natural blood vessel tissue in almost every respect, including the components used.

Drug
Delivery

Unique
fabrication techniques allow us to homogeneously distribute the drug in milligram to nanogram amounts, resulting in optimum performance
and manufacturing capabilities for a variety of delivery methods, such as coatings, injectables, implantables, or transmucosal delivery.
The first planned transmucosal product has been optimized and tested with peptide drugs with better efficacy than oral dosing via swallowing.

6

Orthopedic
Devices

Another
of our materials can be used in a variety of shapes for orthopedic and dental applications. The first products, OrthoGelic™ and
OrthoMetic™, will be aimed at difficult-to-heal, non-union broken bones, by using particles to fill the empty space. The orthopedic